Quantitative Immunofluorescence for T-Cell Activity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing immune-related protein biomarkers in tumor samples are limited, as they typically measure only 1-2 phenotypic cell markers, are subjective, and lack quantitative output, failing to interrogate specific cellular processes or provide spatial resolution, which hinders the identification of anti-tumor immune response quality and quantity.
Innovation Solution
A method involving the measurement of markers for T-lymphocytes, proliferation, and activation in tumor tissue samples using quantitative immunofluorescence or in situ assessment, with predetermined reference levels to determine the suitability of patients for immune checkpoint blocker treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current in situ methods are used to identify cell type, then cell type identification is achieved, but the activity state of immune cells cannot be determined
Solution Approach 1:
The patent segments the assessment of immune cells into multiple independent marker measurements (e.g., PD-1, LAG-3, TIM-3 for activation state; Ki-67 for proliferation). Each marker is measured separately and quantitatively, allowing comprehensive characterization of both cell type and activity state without requiring sample dissociation.
Solution Approach 2:
The in situ measurement platform is designed to perform multiple functions simultaneously: identifying cell types through lineage-specific markers, assessing activation states through checkpoint marker expression, and measuring proliferation through Ki-67 staining. This multi-functional approach eliminates the need for separate assays while maintaining spatial context.
2Measurement precision
If multiplexed assessment of multiple proteins is performed to define activity state, then activity state determination is improved, but the methods become complex and require dissociation or grinding of samples
Solution Approach 1:
The patent employs in situ measurement techniques where the tissue section itself serves as the measurement platform. The endogenous tissue structure provides the spatial context, and the measurement system detects markers directly within this preserved architecture, eliminating the need for external processing steps like dissociation or grinding that would otherwise be required to access intracellular markers.
3Quantity of substance
If existing methods detect immune-related protein biomarkers, then 1-2 phenotypic cell markers can be measured, but the methods are subjective and lack quantitative output
Solution Approach 1:
The patent replaces subjective visual assessment with automated image analysis and quantitative signal processing. Fluorescence or chromogenic signals from immunohistochemical staining are captured by digital imaging systems and processed through algorithms that objectively quantify marker expression levels, providing precise numerical data rather than subjective semi-quantitative scores.
4Loss of information
If in situ measurement with spatial resolution is implemented, then cellular processes and functions can be interrogated, but the methods currently lack the ability to provide this assessment
Solution Approach 1:
The patent adds the dimension of spatial resolution to biomarker measurement by performing all assessments directly within the tissue section context. This allows correlation of marker expression with specific tissue compartments (e.g., tumor core vs. invasive margin, stromal regions) and enables assessment of spatial relationships between different cell types and their functional states, providing insights into cellular processes that cannot be obtained from dissociated cell suspensions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of patients likely to benefit from immune checkpoint therapy by quantitatively assessing T-lymphocyte activity and proliferation, improving treatment selection and patient outcomes in cancers such as non-small cell lung cancer.
Implementation Method 1
The level of the marker for T-lymphocytes, the level of the marker for activation and the level of the marker for proliferation is measured using quantitative immunofluorescence
Data Source
AI summary
The present disclosure provides a method of treating cancer by immune checkpoint blockade, or selecting patients for treatment with immune checkpoint blockers, by detecting tumors with high levels of T-lymphocytes with low levels of activation and proliferation. In various embodiments the tissue sample may be from a conventional biopsy. In various embodiments the cancer may be non-small cell lung cancer.